Healthcare Sector Watch List: Tokai Pharmaceuticals Inc (TKAI), Raptor Pharmaceutical Corp. (RPTP)

0
70

Tokai Pharmaceuticals Inc (NASDAQ:TKAI)

Stock’s Trading Stats:

Tokai Pharmaceuticals Inc (NASDAQ:TKAI) surged 32.48% yesterday and closed at $7.75. The company’s market capitalization is at $180.28 Million with an average trading volume of 49,268.00shares. The total number of Outstanding Shares Held by the company are 22.63 Million.

Recent Press Release:

Tokai Pharmaceuticals Inc (TKAI) on April 6, 2016 declared that administration will present at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 1:40pm ET at The Westin Grand Central in New York City.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP)

Stock’s Trading Stats:

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) closed at $5.81yesterday by showing a increase of 24.41%. The total number of outstanding shares held by the company are 85.24Million with the total market capitalization of $505.00 Million. The number of shares traded on the last trading session are 3.20Million.

Recent Press Release:

Raptor Pharmaceutical Corp. (RPTP) on March 21, 2016 declared that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI® (cysteamine bitartrate) delayed-release capsules for the treatment of nephropathic cystinosis (NC), with Priority Review status. Priority Review provides for a shortened review process of 180 days contrast to a standard 300 days. Raptor estimates, based on information offered by physicians, that there are about 100 individuals affected by nephropathic cystinosis in Canada. PROCYSBI, a cystine depleting agent, is approved in the U.S. for the treatment of NC in adults and children ages two years and older and in all patients with NC in Europe.